Advances in
Bone Cancer Treatment:

Preventing Metastasis and Bone Loss

References

    1.
  • Paget S. The distribution of secondary growths in cancer of the breast. 1889. Cancer Metastasis Rev. 1989;8(2):98-101.
    • 2.
  • Christopher MJ, Liu F, Hilton MJ et al. Suppression of CXCL12 production by bone marrow osteoblasts is a common and critical pathway for cytokine-induced mobilization. Blood. 2009;114(7):1283-4.
    • 3.
  • Shiozawa Y, Havens AM, Jung Y et al. Annexic II/annexinII receptor axis regulates adhesion, migration, homing, and growth of prostate cancer. J Cell Biochem. 2008;105:370-80.
    • 4.
  • Jones DH, Nakashima T, Sanchez OH et al. Regulation of cancer cell migration and bone metastasis by RANKL. Nature. 2006;440(7084):692-6.
    • 5.
  • Kollet O, Dar A, Shivtiel S et al. Osteoclasts degrade endosteal components and promote mobilization of hematopoietic progenitor cells. Nat Med. 2006;12(6):657-64.
    • 6.
  • Hauschka PV, Mavrakos AE, Iafrati MD et al. Growth factors in bone matrix. Isolation of multiple types by affinity chromatography on heparin-Sepharose. J Biol Chem. 1986;261(27):12665-74.
    • 7.
  • Roodman GD. Role of stromal-derived cytokines and growth factors in bone metastasis. Cancer. 2003;97(3 Suppl):733-8.
    • 8.
  • Mancino AT, Klimberg VS, Yamamoto M et al. Breast cancer increases osteoclas-togenesis by secreting M-CSF and upregulating RANKL in stromal cells. J Surg Res. 2001;100(1):18-24.
    • 9.
  • Chirgwin JM, Guise TA. Molecular mechanisms of tumor-bone interactions in osteolytic metastases. Crit Rev Eukaryot Gene Expr. 2000;10(2):159-78.
    • 10.
  • Oshima T, Abe M, Asano J et al. Myeloma cells suppress bone formation by secreting a soluble Wnt inhibitor, sFRP-2. Blood. 2005;106(9):3160-5.
    • 11.
  • Park BK, Zhang H, Zeng Q et al. NF-kappaB in breast cancer cells promotes osteolytic bone metastasis by inducing osteoclastogenesis via GM-CSF. Nat Med. 2007;13(1):62-9.
    • 12.
  • Bandyopadhyay A, Agyin JK, Wang L et al. Inhibition of pulmonary and skeletal metastasis by a transforming growth factor-beta type I receptor kinase inhibitor. Cancer Res. 2006;66(13):6714-21.
    • 13.
  • Ehata S, Hanyu A, Fujime M et al. Ki26894, a novel transforming growth factor-beta type I receptor kinase inhibitor, inhibits in vitro invasion and in vivo bone metastasis of a human breast cancer cell line. Cancer Sci. 2007;98(1):127-33.
    • 14.
  • Kang Y, Siegel PM, Shu W et al. A multigenic program mediating breast cancer metastasis to bone. Cancer Cell. 2003;3(6):537-49.
    • 15.
  • Tian E, Zhan F, Walker R et al. The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. N Engl J Med. 2003;349(26):2483-94.
    • 16.
  • Politou MC, Heath DJ, Rahemtulla A et al. Serum concentrations of Dickkopf-1 protein are increased in patients with multiple myeloma and reduced after autologous stem cell transplantation. Int J Cancer. 2006;119(7):1728-31.
    • 17.
  • Westendorf JJ, Kahler RA, Schroeder TM. Wnt signaling in osteoblasts and bone diseases. Gene. 2004;341:19-39.
    • 18.
  • Yaccoby S, Ling W, Zhan F et al. Antibody-based inhibition of DKK1 suppresses tumor-induced bone resorption and multiple myeloma growth in vivo. Blood. 2007;109(5):2106-11.
    • 19.
  • Edwards CM, Edwards JR, Lwin ST et al. Increasing Wnt signaling in the bone marrow microenvironment inhibits the development of myeloma bone disease and reduces tumor burden in bone in vivo. Blood. 2008;111(5):2833-42.
    • 20.
  • Qiang YW, Shaughnessy JD Jr, Yaccoby S. Wnt3a signaling within bone inhibits multiple myeloma bone disease and tumor growth. Blood. 2008;112(2):374-82.
    • 21.
  • Roato I, D'Amelio P, Gorassini E et al. Osteoclasts are active in bone forming metastases of prostate cancer patients. PLoS One. 2008;3(11):e3627.
    • 22.
  • Guise TA, Yin JJ, Mohammad KS. Role of endothelin-1 in osteoblastic bone metastases. Cancer. 2003;97(3 Suppl):779-84.
    • 23.
  • Kasperk CH, Borcsok I, Schairer HU et al. Endothelin-1 is a potent regulator of human bone cell metabolism in vitro. Calcif Tissue Int. 1997;60(4):368-74.
    • 24.
  • Nelson JB, Hedican SP, George DJ et al. Identification of endothelin-1 in the pathophysiology of metastatic adenocarcinoma of the prostate. Nat Med. 1995;1(9):944-9.
    • 25.
  • Hall CL, Bafico A, Dai J et al. Prostate cancer cells promote osteoblastic bone metastases through Wnts. Cancer Res. 2005;65(17):7554-60.
    • 26.
  • Hall CL, Daignault SD, Shah RB et al. Dickkopf-1 expression increases early in prostate cancer development and decreases during progression from primary tumor to metastasis. Prostate. 2008;68(13):1396-404.
    • 27.
  • Clines GA, Mohammad KS, Bao Y et al. Dickkopf homolog 1 mediates endothelin-1-stimulated new bone formation. Mol Endocrinol. 20007;21(2):486-98.
    • 28.
  • Coleman RE. Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin Cancer Res. 2006;12(20Pt2)6243s-9s.
    • 29.
  • Rosen LS, Gordon D, Kaminski M et al. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial. Cancer J. 2001;7(5):377-87.
    • 30.
  • Saad F, Gleason DM, Murray R et al. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst. 2004;96(11):879-82.
    • 31.
  • Rosen LS, Gordon D, Tchekmedyian S et al. Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial—the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group. J Clin Oncol. 2003;21(16):3150-7.
    • 32.
  • Rosen LS, Gordon D, Tchekmedyian NS et al. Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, Phase III, double-blind, placebo-controlled trial. Cancer. 2004;100(12):2613-21.
    • 33.
  • Hillner B, Ingle J, Berenson J et al. American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in breast cancer. J Clin Oncol. 2003;21:4042-57.
    • 34.
  • Berenson J, Hillner B, Kyle R et al. American Society of Clinical Oncology clinical practice guidelines: the role of bisphosphonates in multiple myeloma. J Clin Oncol. 2002;20(17):3719-36.
    • 35.
  • Conte P, Guarneri V. Safety of intravenous and oral bisphosphonates and compliance with dosing regimens. Oncologist. 2004;9 (Suppl 4):28-37.
    • 36.
  • Hoff AO, Toth BB, Altundag K et al. Osteonecrosis of the jaw in patients receiving intravenous bisphosphonate therapy. J Clin Oncol. 2006;24(18S):abstr 8528.
    • 37.
  • Dimopoulos M, Kastritis E, Anagnostopoulos A et al. Osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates: evidence of increased risk after treatment with zoledronic acid. Haematologica. 2006;91(7):968-71.
    • 38.
  • Lipton A, Steger GG, Figueroa J et al. Randomized active-controlled phase II study of denosumab efficacy and safety in patients with breast cancer-related bone metastases J Clin Oncol. 2007;25(28):4431-7.
    • 39.
  • Fizazi K, Lipton A, Mariette X et al. A randomized phase 2 trial of denosumab in patients with bone metastases from prostate, breast cancer or other neoplasms after IV bisphosphonates. J Clin Oncol. 2009;27(10):1564-71.
    • 40.
  • Stopeck A, de Boer R, Fujiwara Y et al. A comparison of denosumab versus zoledronic acid for the prevention of skeletal-related events in breast cancer patients with bone metastases. Proceedings of the 32nd Annual San Antonio Breast Cancer Symposium, San Antonio, TX, Dec 10-13, 2009 (abstr 22).
    • 41.
  • Henry D, von Moos R, Vadhan-Ral S et al. A double-blind randomized study of denosumab versus zoledronic acid for the treatment of bone metastases in patients with solid tumours (excluding breast and prostate) or multiple myeloma. Eur J Cancer. 2009;7 (Suppl 3):abstr 20LBA 12.
    • 42.
  • Lipton A. Future treatment of bone metastases. Clin Cancer Res. 200612(20Pt2):6305s-8s.
    • 43.
  • McClung M, Bone H, Cosman F et al. A randomized, double-blind, placebo-controlled study of odanacatib (MK-822) in the treatment of postmenopausal women with low bone mineral density: 24 month results. Presented at the 30th annual meeting of the American Society for Bone and Mineral Research, Montreal, Quebec, Sept 12-16, 2008 (abstr 1291).
    • 44.
  • Jensen AB, Olmeo N, Wynne C et al. Effect of cathepsin k inhibition on suppression of bone resorption in women with breast cancer and established bone metastases in a 4-week, double-blind, randomized controlled trial. J Clin Oncol. 2008;26 (Suppl):abstract 1023.
    • 45.
  • Carducci MA, Padley RJ, Breul J et al. Effect of endothelin-A receptor blockade with atrasentan on tumor progression in men with hormone-refractory prostate cancer: a randomized, phase II, placebo-controlled trial. J Clin Oncol. 2003;21(4):679-89.
    • 46.
  • Carducci MA, Saad F, Abrahamsson PA et al. A phase 3 randomized controlled trial of the efficacy and safety of atrasentan in men with metastatic hormone-refractory prostate cancer. Cancer. 2007;110(9):1959-66.
    • 47.
  • Nelson JB, Love W, Chin JL et al. Phase 3 randomized, controlled trial of atrasentan in patients with nonmetastatic, hormone-refractory prostate cancer. Cancer. 2008;113(9):2478-87.
    • 48.
  • Michaelson MD, Kaufman DS, Kantoff P et al. Randomized phase II study of atrasentan alone or in combination with zoledronic acid in men with metastatic prostate cancer. Cancer. 2006;107(3):530-5.
    • 49.
  • Marzia M, Sims NA, Voit S et al. Decreased c-Src expression enhances osteoblast differentiation and bone formation. J Cell Biol. 2000;151(2):311-20.
    • 50.
  • Rucci N, Susa M, Teti A. Inhibition of protein kinase c-Src as a therapeutic approach for cancer and bone metastases. Anticancer Agents Med Chem. 2008;8(3):342-9.
    • 51.
  • Roodman GD. Bone building with bortezomib. J Clin Invest. 2008;118(2):462-4.
    • 52.
  • Guiliani N, Morandi F, Tagliaferri S et al. The proteosome inhibitor bortezomib affects osteoblast differentiation in vitro and in vivo in multiple myeloma patients. Blood. 2007;110(1):334-8.
    • 53.
  • Khosla S, Melton LJ III, Atkinson EJ et al. Relationship of serum sex steroid levels to longitudinal changes in bone density in young versus elderly men. J Clin Endocrinol Metab. 2001;86(8):3555-61.
    • 54.
  • Shahinian VB, Kuo YF, Freeman JL et al. Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med. 2005:352(2):154-64.
    • 55.
  • Smith MR, Lee W-C, Brandman J et al. Gonadotropin-releasing hormone agonists and fracture risk: a claims-based cohort study of men with nonmetastatic prostate cancer. J Clin Oncol. 2005;23:7897-7903.
    • 56.
  • Howell A, Cuzick J, Baum M et al. Results of the ATAC trial (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years adjuvant treatment for breast cancer. Lancet. 2005;365(9453):60-62.
    • 57.
  • Coates AS, Keshaviah A, Thurlimann B et al. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1–98. J Clin Oncol. 2007;25:486-92.
    • 58.
  • Coombes R, Kilburn L, Snowdon C et al. Survival and safety of exemestane versus tamoxifen after 2–3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial. Lancet. 2007;369:559-70.
    • 59.
  • Guise TA. Bone loss and fracture risk associated with cancer therapy. Oncologist. 2006;11(10):1121-31.
    • 60.
  • Aapro MS. Long-term implications of bone loss in breast cancer. Breast. 2004;13(Suppl 1):S29-37.
    • 61.
  • Coleman RE, Banks LM, Girgis SI et al. Skeletal effects of exemestane on bone mineral density, bone biomarkers, and fracture incidence in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES): a randomized controlled study. Lancet Oncol. 2007;9:119-27.
    • 62.
  • Barry MJ, Delorenzo MA, Walker-Corkery ES et al. The rising prevalence of androgen deprivation among older American men since the advent of prostate-specific antigen testing: a population-based cohort study. BJU Int. 2006;98(5):973-
    • 63.
  • Mittan D, Lee S, Miller E et al. Bone loss following hypogonadism in men with prostate cancer treated with GnRH analogs. J Clin Endocrinol Metab. 2002;87(8):3656-61.
    • 64.
  • National Comprehensive Cancer Network. NCCN clinical practice guidelines. Prostate cancer V.1.2009. NCCN 2009. Available here.
    • 65.
  • Eastell R. Treatment of postmenopausal osteoporosis. N Engl J Med. 1998:388(11):736-46.
    • 66.
  • National Osteoporosis Foundation. Clinician's guide to prevention and treatment of osteoporosis. Washington, DC, 2008.
    • 67.
  • Bone and Cancer Foundation. Vitamin D deficiency: information for cancer patients. Bone and Cancer Foundation 2008. Available here.
    • 68.
  • Delmas PD, Balena R, Confravreux E et al. Bisphosphonate risedronate prevents bone loss in women with artificial menopause due to chemotherapy of breast cancer: a double blind placebo-controlled study. J Clin Oncol.1997;15:955-62.
    • 69.
  • Greenspan SL, Brufsky A, Lembersky BC et al. Risedronate prevents bone loss in breast cancer survivors: a 2-year randomized, double-blind, placebo-controlled clinical trial. J Clin Oncol. 2008:26(16):2644-52.
    • 70.
  • Saarto T, Blomqvist C, Valimaki M et al. Chemical castration induced by adjuvant CMF chemotherapy causes rapid bone loss that is reduced by clodronate: a randomized study in premenopausal breast cancer patients. J Clin Oncol.1997;15:1341-7.
    • 71.
  • Gnant M, Mlineritsch B, Schippinger W et al. Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N Engl J Med. 2009;360:679-91. Erratum in: N Engl J Med. 2009;360:2379.
    • 72.
  • Brufsky A, Harker WG, Beck JT et al. Zoledronic acid inhibits adjuvant letrozole-induced bone loss in postmenopausal women with early breast cancer. J Clin Oncol. 2007;25(7):829-36.
    • 73.
  • Ryan CW, Huo D, Demers LM et al. Zoledronic acid initiated during the first year of androgen deprivation therapy increases bone mineral density in patients with prostate cancer. J Urol. 2006;176(3):972-8.
    • 74.
  • Michaelson MD, Kaufman DS, Lee H et al. Randomized controlled trial of annual zoledronic acid to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer. J Clin Oncol. 2007:25(9):1038-42.
    • 75.
  • Smith MR, Malkowicz SB, Chu R et al. Toremifene increases bone mineral density in men receiving androgen deprivation therapy for prostate cancer: interim analysis of a multicenter phase 3 clinical study. J Urol. 2008:179(1):152-5.
    • 76.
  • Ellis G, Bone JG, Chlebowski R et al. Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer. J Clin Oncol. 2008:26(30):4875-82.
    • 77.
  • Smith MR, Egerdie B, Hernandez Toriz N et al. Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N Engl J Med. 2009;361:745-
    • 78.
  • Powles T, Paterson A, McCloskey E et al. Reduction in bone relapse and improved survival with oral clodronate for adjuvant treatment of operable breast cancer. Breast Cancer Res. 2006;8:R13.
    • 79.
  • Diel IJ, Jaschke A, Solomayer EF et al. Adjuvant oral clodronate improves the overall survival of primary breast cancer patients with micrometastases to the bone marrow: a long-term follow-up. Ann Oncol. 2008;12:2007-11.
    • 80.
  • Saarto T, Blomqvist C, Virkkunen P et al. Adjuvant clodronate treatment does not reduce the frequency of skeletal metastases in node-positive breast cancer patients: 5-year results of a randomized controlled trial. J Clin Oncol. 2001;19:10-7.
    • 81.
  • Ha TC, Li H. Meta-analysis of clodronate and breast cancer survival. Br J Cancer. 2007;96:1796-801.
    • 82.
  • Kristensen B, Ejlertsen B, Mouridsen HT et al. Bisphosphonate treatment in primary breast cancer: results from a randomised comparison of oral pamidronate versus no pamidronate in patients with primary breast cancer. Acta Oncol. 2008;47:740-6.
    • 83.
  • Coleman RE, Houston S, James I et al. Preliminary results of the use of urinary excretion of pyridinium crosslinks for monitoring metastatic bone disease. Br J Cancer. 1992;65:766-8.
    • 84.
  • Cramer JA, Amonkar MM, Hebborn A et al. Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis. Curr Med Res Opin. 2005;21:1453-60.
    • 85.
  • Rack B, Schindelbeck C, Strobl B et al. Efficacy of zoledronate in treating persisting isolated tumor cells in bone marrow in patients with breast cancer. A phase II pilot study. Dtsch Med Wochenschr. 2008;133:285-9.
    • 86.
  • Lin A, Park J, Melisko M et al. Zoledronic acid as adjuvant therapy for women with early stage breast cancer and occult tumor cells in bone marrow. Proceedings of the 30th Annual San Antonio Breast Cancer Symposium, San Antonio, TX, Dec 13-16, 2007 (abstr 510).
    • 87.
  • Gnant M, Mlineritsch B, Luschin-Ebengreuth G et al. Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy. Lancet Oncol. 2008;9:840-9.
    • 88.
  • Shiozawa Y, Havens AM, Pienta KJ et al. The bone marrow niche: habitat to hematopoietic and mesenchymal stem cells, and unwitting host to molecular parasites. Leukemia. 2008;22:941-50.
    • 89.
  • Eidtmann H, Bundred NJ, DeBoer R et al. The effect of zoledronic acid on aromatase inhibitor associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36 months follow-up of ZO-FAST. Proceedings of the 31st Annual San Antonio Breast Cancer Symposium, San Antonio, TX, Dec 10-14, 2008 (abstr 44).
    • 90.
  • Brufsky AM, Bosserman LD, Caradonna RR et al. Zoledronic acid effectively prevents aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: Z-FAST study 36-month follow-up results. Clin Breast Cancer. 2009;9:77-85.
    • 91.
  • Coleman R, Bundred N, De Boer R et al. Impact of zoledronic acid in post-menopausal women with early breast cancer receiving adjuvant letrozole: Z-FAST, ZO-FAST, and E-ZO-FAST. Proceedings of the 34th annual meeting of the European Society for Medical Oncology, Berlin, Germany, Sept 20-24, 2009 (abstr 4082).
    • 92.
  • AZURE trial. Available here (accessed 12/18/2009).
    • 93.
  • Southwestern Oncology Group (SWOG) S037 Trial. Available here (accessed 12/22/09).
    • 94.
  • Dearnaley DP, Mason MD, Parmar MK et al. Survival benefit with oral sodium clodronate in metastatic but not localised prostate cancer: long-term results of MRC PR04 & PR05. Presented at the American Society of Clinical Oncology Genitourinary Cancer Symposiuim, Orlando, FL, Feb 26-28, 2009 (abstr 6).
    • 95.
  • Smith MR, Kabbinavar F, Saad F et al. Natural history of rising serum prostate-specific antigen in men with castrate nonmetastatic prostate cancer. J Clin Oncol. 2005;23(13):2918-25.
    • 96.
  • Stopek A, Body JJ, Fugiwara Y et al. Denosumab versus zoledronic acid for the treatment of breast cancer patients with bone metastases: results of a randomized phase 3 study. Eur J Cancer. 2009;7 (Suppl 3) (abstr 2LBA, 2-3).
    • 97.
  • Costa L, Major PP. Effect of bisphosphonates on pain and quality of life in patients with bone metastases. Nat Clin Pract Oncol. 2009;6(3):163-74.
    • 98.
  • Coleman RE. Risks and benefits of bisphosphonates. Br J Cancer. 2008;3;98(11):1736-40.
    • 99.
  • Stresing V, Daubine F, Benzaid I et al. Bisphosphonates in cancer therapy. Cancer Lett. 2007;8;257(1):16-35.
    • 100.
  • Lee MV, Fong EM, Singer FR et al. Bisphosphonate treatment inhibits the growth of prostate cancer cells. Cancer Res. 2001;61:2602-8.
    • 101.
  • Senaratne SG, Pirianov G, Mansi JL et al. Bisphosphonates induce apoptosis in human breast cancer cell lines. Br J Cancer. 2000;82:1459-68.
    • 102.
  • Daubine F, Le Gall C, Gasser J et al. Antitumor effects of clinical dosing regimes of bisphosphonates in experimental breast cancer bone metastases. J Natl Cancer Inst. 2007;99:322-30.
    • 103.
  • Corey E, Brown LG, Quinn JE et al. Zoledronic acid exhibits inhibitory effects on osteoblastic and osteolytic metastases of prostate cancer. Clin Cancer Res. 2003;9(1):295-306.
    • 104.
  • Brown HK, Holen I. Anti-tumor effects of bisphosphonates–what have we learned from in vivo models? Curr Cancer Drug Targets. 2009;9(7):807-23.
    • 105.
  • Guise TA. Breaking down bone: new insight into site-specific mechanisms of breast cancer osteolysis mediated by metalloproteinases. Genes Dev. 2009;23(18):2117-23.
    • 106.
  • Wakchoure S, Merrell MA, Aldrich W et al. Bisphosphonates inhibit the growth of mesothelioma cells in vitro and in vivo. Clin Cancer Res. 2006;12:2862-8.
    • 107.
  • Matsumoto S, Kimura S, Segawa H et al. Efficacy of the third-generation bisphosphonate, zoledronic acid alone and combined with anti-cancer agents against small cell lung cancer cell lines. Lung Cancer. 2005;47:31-9.
    • 108.
  • Li YY, Chang JW, Chou WC et al. Zoledronic acid is unable to induce apoptosis, but slows tumor growth and prolongs survival for non-small-cell lung cancers. Lung Cancer. 2008;59(2):180-91.
    • 109.
  • Thudi NK, Martin CK, Nadella MV et al. Zoledronic acid decreased osteolysis but not bone metastasis in a nude mouse model of canine prostate cancer with mixed bone lesions. Prostate. 2008;68(10):1116-25.
    • 110.
  • van der Pluijm G, Que I, Sijmons B et al. Interference with the microenvironmental support impairs the de novo formation of bone metastases in vivo. Cancer Res. 2005;65(17):7682-90.
    • 111.
  • Winter MC, Thorpe HC, Burkinshaw R et al. The addition of zoledronic acid to neoadjuvant chemotherapy may influence pathological response-exploratory evidence for direct antitumor activity in breast cancer. Proceedings of the 31st Annual San Antonio Breast Cancer Symposium, San Antonio, TX, Dec 10-14, 2008 (abstr 5101).
    • 112.
  • Chlebowski R, Chen Z, Cauley JA et al. Oral bisphosphonates and breast cancer: prospective results from the Women's Health Initiative (WHI). Proceedings of the 32nd Annual San Antonio Breast Cancer Symposium, San Antonio, TX, Dec 10-14, 2008 (abstr 21).
    • 113.
  • Rennert G, Pinchev M, Rennert HS. Use of bisphosphonates and risk of post-menopausal breast cancer. Proceedings of the 32nd Annual San Antonio Breast Cancer Symposium, San Antonio, TX, Dec 10-14, 2008 (abstr 27).
    • 114.
  • Brubaker KD, Brown LG, Vessella RL et al. Administration of zoledronic acid enhances the effects of docetaxel on growth of prostate cancer in the bone environment. BMC Cancer. 2006;17:6:15
    • 115.
  • Santini D, Caraglia M, Vincenzi B et al. Mechanisms of disease: preclinical reports of antineoplastic synergistic action of bisphosphonates. Nat Clin Pract Oncol. 2006;3(6):325-38.
    • 116.
  • Heymann D, Ory B, Blanchard F et al. Enhanced tumor regression and tissue repair when zoledronic acid is combined with ifosfamide in rat osteosarcoma. Bone. 2005;37(1):74-86.
    • 117.
  • Segawa H, Kimura S, Kuroda J et al. Zoledronate synergises with imatinib mesylate to inhibit Ph primary leukaemic cell growth. Br J Haematol. 2005;130(4):558-
    • 118.
  • Ottewell PD, Moenkkoenen H, Jones M et al. Antitumor effects of doxorubicin followed by zoledronic acid in a mouse model of breast cancer. J Natl Cancer Inst. 2008;100(16):1167-78.
    • 119.
  • Ottewell PD, Lefley DV, Cross SS et al. Sustained inhibition of tumor growth and prolonged survival following sequential administration of doxorubicin and zoledronic acid in a breast cancer model. Int J Cancer. 2010;126(2):522-32.
    • 120.
  • Ottewell PD, Deux B, Moenkkoenen H et al. Differential effect of doxorubicin and zoledronic acid on intraosseous versus extraosseous breast tumor growth in vivo. Clin Cancer Res. 2008;14(14):4658-66.
    • 121.
  • van Beek ER, Lowik CW, van Wijngaarden J et al. Synergistic effect of bisphosphonate and docetaxel on the growth of bone metastasis in an animal model of established metastatic bone disease. Breast Cancer Res Treat. 2009;118(2):307-
    • 122.
  • Thomas RJ, Guise TA, Yin J et al. Breast cancer cells interact with osteoblasts to support osteoclast formation. Endocrinology. 1999;140(10):4451-8.
    • 123.
  • Palmqvist P, Persson E, Conaway HH et al. IL-6, leukemia inhibitory factor, and oncostatin M stimulate bone resorption and regulate the expression of receptor activator of NF-kappa B ligand, osteoprotegerin, and receptor activator of NF-kappa B in mouse calvariae. J Immunol. 2002;169(6):3353-62.
    • 124.
  • Horwood NJ, Elliott J, Martin TJ et al. Osteotropic agents regulate the expression of osteoclast differentiation factor and osteoprotegerin in osteoblastic stromal cells. Endocrinology. 1998;139(11):4743-6.
    • 125.
  • Bendre MS, Montague DC, Peery T et al. Interleukin-8 stimulation of osteoclastogenesis and bone resorption is a mechanism for the increased osteolysis of metastatic bone disease. Bone. 2003;33(1):28-37.
    • 126.
  • Tat SK, Pelletier JP, Lajeunesse D et al. Differential modulation of RANKL isoforms by human osteoarthritic subchondral bone osteoblasts: influence of osteotropic factors. Bone. 2008;43(2):284-91.
    • 127.
  • Odero-Marah VA, Wang R, Chu G et al. Receptor activator of NF-kappaB Ligand (RANKL) expression is associated with epithelial to mesenchymal transition in human prostate cancer cells. Cell Res. 2008;18(8):858-70.
    • 128.
  • Armstrong AP, Miller RE, Jones JC et al. RANKL acts directly on RANK-expressing prostate tumor cells and mediates migration and expression of tumor metastasis genes. Prostate. 2008;68(1):92-104.
    • 129.
  • Hwang C, Chung H, Kang Y et al. Effects of RANKL on breast cancer cell lines. J Bone Miner Res. 2002;17(Suppl 1):S310.
    • 130.
  • Holen I, Cross SS, Neville-Webbe HL et al. Osteoprotegerin (OPG) expression by breast cancer cells in vitro and breast tumours in vivo—a role in tumour cell survival? Breast Cancer Res Treat. 2005;92(3):207-15.
    • 131.
  • Fisher JL, Thomas-Mudge RJ, Elliott J et al. Osteoprotegerin overexpression by breast cancer cells enhances orthotopic and osseous tumor growth and contrasts with that delivered therapeutically. Cancer Res. 2006;66(7):3620-8.
    • 132.
  • Kapoor P, Suva LJ, Welch DR et al. Osteoprotegrin and the bone homing and colonization potential of breast cancer cells. J Cell Biochem. 2008;103(1):30-41.
    • 133.
  • Nicolin V, Narducci P. Soluble TRAIL could enhance bone destruction acting on Rank-ligand in estrogen-independent human breast cancer cell line MDA-MB-231. Acta Histochem. 2008; [Epub ahead of print].
    • 134.
  • Canon JR, Roudier M, Bryant R et al. Inhibition of RANKL blocks skeletal tumor progression and improves survival in a mouse model of breast cancer bone metastasis. Clin Exp Metastasis. 2008;25(2):119-29.
    • 135.
  • Zheng Y, Zhou H, Brennan K et al. Inhibition of bone resorption, rather than direct cytotoxicity, mediates the anti-tumour actions of ibandronate and osteoprotegerin in a murine model of breast cancer bone metastasis. Bone. 2007;40(2):471-8.
    • 136.
  • Cross SS, Yang Z, Brown NJ et al. Osteoprotegerin (OPG)—a potential new role in the regulation of endothelial cell phenotype and tumour angiogenesis? Int J Cancer. 2006;118(8):1901-8.